Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (NCT01497262), a non-randomized phase 3 study. The primary outcome is Number of Participants With Adverse Events as a Measure of Safety and Tolerability.

2. Clinical Question

The clinical question is descriptive: what adverse events were recorded among patients receiving fingolimod in this study? The design can describe events observed during the study, but it cannot isolate the effect of fingolimod from the background occurrence of symptoms or events in this population. Without a concurrent comparison group, the recorded counts do not show whether event frequency differed from what would have occurred under another treatment or without study treatment.

The primary outcome timeframe is recorded as 28 weeks, while the official title describes a 4-month study. The registry record does not explain this difference. It also lists adverse events of special interest as a secondary outcome, including bradyarrhythmia, blood-pressure increase, liver transaminase elevations, infections, and macula oedema. Those listed topics indicate areas of safety interest, but their outcome results are not included in the registry entries.

3. Trial Design

The registry describes a phase 3, open-label, multi-center study with non-randomized allocation and a single-group model. Its official title characterizes it as a 4-month study exploring the safety and tolerability of fingolimod 0.5 mg in patients with RRMS. The arm description states that fingolimod was taken orally once daily for 4 months. Because there was one treatment group and no random allocation, there is no randomized control comparison for interpreting the adverse-event counts.

Enrollment was 162. The primary outcome’s analysis population is the safety set, defined as all patients who received at least one dose of study drug. The adverse-event record lists 162 participants at risk for serious events and 162 at risk for other events. The primary outcome timeframe is listed separately as 28 weeks. The registry record does not explain how that timeframe relates to the 4-month duration in the title and arm description, so the two descriptions should not be treated as interchangeable or reconciled by assumption.

The study is recorded as completed. Its recorded start is 2012-02, and primary completion is 2014-04. Novartis Pharmaceuticals is listed as the sponsor. The brief summary says the study aimed to evaluate safety and tolerability and generate additional data in a patient population resembling routine medical care. The registry record does not report details that would establish how closely the enrolled population matched routine-care patients.

Open-label means that masking was absent. Participants and study personnel were not blinded according to the registry’s masking field. This matters particularly for safety reporting: awareness of treatment can influence whether symptoms are noticed, reported, assessed, or classified. That possibility does not show that reporting was biased in this study; it is a design consideration when interpreting subjective or symptom-based outcomes.

Non-randomized, single-group safety results are useful as descriptions of what was recorded in the treated group. They do not provide the like-for-like comparison needed to estimate a treatment-attributable difference in risk. The registry itself flags that the arms are not a like-for-like control comparison; in this study, no second arm is listed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety set includes all patients who received at least one dose of study drug

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The Enrolled Set (ENR) included all patients who signed the informed consent and enrolled in study

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Adverse Events as a Measure of Safety and Tolerability, measured over 28 weeks.

The primary endpoint is titled “Number of Participants With Adverse Events as a Measure of Safety and Tolerability.” It is a count of participants, rather than a continuous measurement such as a laboratory value. The registry defines any adverse event as the occurrence of any symptom regardless of intensity grade. It separately describes serious adverse events as medical occurrences resulting in death, being life-threatening, requiring or prolonging hospitalization, or resulting in persistent or significant disability or incapacity.

Counting participants with events is a direct way to describe how many people in the safety set had an event during the stated observation period. It can be useful for safety monitoring because the occurrence of an event matters even when the event is not the primary focus of a trial designed to assess efficacy. The registry defines the safety set as all patients who received at least one dose of study drug, so the endpoint is not defined as an intention-to-treat comparison between randomized groups.

The primary outcome timeframe is listed as 28 weeks. The intervention description and official title state 4 months. The registry record does not explain the difference. The posted adverse-event figures list serious and other adverse-event counts, but do not give a separate result for the primary outcome’s all-adverse-event count as worded. The record also does not report event severity gradations for the non-serious events, duration, recurrence, or an analysis relating events to exposure time.

This endpoint helps describe observed safety experience, but a count alone does not establish causation. In a single-group study, it cannot distinguish events caused by treatment from events related to the condition, other circumstances, or background occurrence.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count measure?

A participant count records how many people met an outcome definition during the observation period. For adverse events, this is different from counting every episode: one participant may experience more than one event, while a participant-level count generally records whether the person experienced the specified outcome. The registry’s primary outcome is phrased as a number of participants. The adverse-event record separately gives affected-participant counts for serious events and other events.

Counts are most interpretable when the population, event definition, observation window, and denominator are clear. The safety set is defined as all patients who received at least one dose of study drug. The adverse-event record lists 162 at risk for serious and other events. The registry’s timeframe for the primary outcome is 28 weeks, whereas the intervention description says fingolimod was taken for 4 months. The record does not explain the relationship between those durations or identify a separate observation window for each adverse-event category.

Why does the single-group design matter?

A comparative treatment effect is usually expressed by contrasting outcomes in groups that represent the treatment strategies being compared. Random allocation is one method for making groups comparable, on average, with respect to factors that can affect outcomes. This study is classified as non-randomized and single-group, and no comparator group is listed. It therefore supplies a description of events in the fingolimod group, not a randomized estimate of a difference between treatments.

Without a comparator, the observed events cannot be separated into those attributable to treatment and those that might have occurred because of RRMS, other health circumstances, or background event rates. Nor can the observed count show what the event count would have been for the same population under a different treatment strategy. This is a limitation of the design’s capacity for causal comparison, not a claim that the events were unrelated to treatment.

How should serious and other events be read?

The registry defines serious adverse events by consequences including death, life-threatening events, hospitalization or prolonged hospitalization, and persistent or significant disability or incapacity. The “other” category is reported separately from serious events. The record does not provide enough detail to determine whether the categories were mutually exclusive at the participant level, so their counts should not be added. Event counts also do not necessarily represent event episodes, since the record reports participants affected rather than a total number of occurrences.

The listed serious-event terms carry percentages, but the registry record does not state the denominator basis for those percentages. It also does not say whether terms were coded at a particular level of specificity, whether multiple terms could be assigned to the same event, or how the listed terms were selected. These uncertainties limit interpretation of the percentages as measures of comparative frequency.

What is the role of uncertainty?

An estimate based on observed participants is subject to sampling uncertainty: another set of similar participants could produce different counts. Confidence intervals are a common way to communicate the range of values reasonably compatible with the data under a statistical model. They do not guarantee that the underlying value lies within the interval, and their interpretation depends on the model and data collection. No confidence intervals or inferential analyses are reported in the registry record for the adverse-event results.

For event data, precision can be limited when events are uncommon. In general, fewer observed events tend to provide less information about an underlying event rate than more observed events. Over-dispersion is a general concern when event counts vary more across individuals or settings than a simple statistical model expects; allowing for that extra variation can affect uncertainty estimates. The registry record does not report an event-rate model, a dispersion assessment, or a model-based comparison, so such methods should not be attributed to this study.

What can planning calculations tell readers?

Sample-size calculations are planning illustrations, not observed outcomes and not evidence that a study had a particular probability of detecting an effect. The planning assumptions recorded for the calculations specify a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is defined as a stated fraction of the observed effect. The record does not provide the numerical planning results in the registry record for this analysis.

Those assumptions describe a hypothetical two-arm calculation. This trial is recorded as a single-group study, so a two-arm planning illustration should not be mistaken for the actual design or for an analysis of its observed adverse-event counts. Any planning sample size would depend on the chosen effect and assumptions; it would not be an observed power calculation and would not repair the absence of a control group.

The registry reports zero analyses. That means no analyses are recorded in the available registry entry; it does not show that no analysis was conducted outside the registry. The statistical analysis plan, methods for handling repeated events, adjustment for covariates, and inferential procedures are not reported in the registry record. Interpretations should therefore remain tied to the descriptive counts that are recorded.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists two outcome measures, including the primary adverse-event outcome and a secondary outcome concerning adverse events of special interest. The secondary outcome names bradyarrhythmia, blood-pressure increase, liver transaminase elevations, infections, and macula oedema. The registry record does not report a multiplicity strategy, such as how conclusions would be adjusted when several outcomes or event categories are examined. Without such a strategy, individual findings should be treated as descriptive rather than as a set of confirmatory tests.

The registry records zero analyses. It does not report a statistical analysis plan, a hierarchy for testing outcomes, adjustment variables, or methods for dealing with repeated events. No inferential tests or confidence intervals for the adverse-event results are available in the registry record. These omissions do not establish that the study team performed no analyses; they mean that the methods are not reported in the registry record.

The safety set includes all patients who received at least one dose of study drug. The adverse-event record lists 162 at risk for serious events and 162 at risk for other events. The registry record does not describe missing-data procedures, exclusions after treatment began, loss to follow-up, completeness of adverse-event reporting, or how participants with incomplete observation were handled. It also does not report an intention-to-treat analysis population. Consequently, readers cannot assess from the registry record whether incomplete follow-up could have affected the observed counts.

Outcome timing is also not fully explained: the primary outcome timeframe is 28 weeks, while the study title and intervention description state 4 months. The registry record does not clarify whether the difference reflects treatment duration, safety follow-up, or another convention. This uncertainty limits interpretation of the period over which the participant counts were accumulated.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: multiple sclerosis relapse (1.9%), gastroenteritis (1.2%), leukopenia (0.6%), gastroenteritis viral (0.6%), urinary tract infection (0.6%).

The serious adverse-event record lists 12 affected participants among 162 at risk. The other-adverse-event record lists 63 affected participants among 162 at risk. These are two separate entries for the fingolimod group, not a comparison with another arm. The record does not say whether a participant could be counted in both categories, so the counts should not be added or treated as mutually exclusive groups.

The serious-event definition includes medical occurrences resulting in death, being life-threatening, requiring hospitalization or prolonging hospitalization, or causing persistent or significant disability or incapacity. The listed serious-event terms include multiple sclerosis relapse at 1.9%, gastroenteritis at 1.2%, and leukopenia, viral gastroenteritis, urinary tract infection, and increased fibrin D dimer at 0.6% each. The denominator for these percentages is not reported in the registry record.

The record lists no death count. That absence should not be interpreted as evidence that no deaths occurred; the field is not populated in the recorded details. Nor do event terms alone establish that treatment caused an event. The results are descriptive safety observations in a single-group, open-label study, and the registry record does not report a control comparison or uncertainty intervals for these figures.

12. What the Result Does, and Does Not, Mean

The results establish that the registry recorded serious and other adverse-event counts in the fingolimod group: 12 participants were listed with serious adverse events and 63 with other adverse events, with 162 at risk in each category. The record also identifies several serious-event terms and their reported percentages. These observations are relevant to describing the safety experience captured in this study, using its definitions and recorded observation period.

They do not establish how often the same events would have occurred in a comparable group receiving a different treatment, or no study treatment. With one non-randomized group and no comparator, it is not possible to estimate a treatment-versus-control difference from these results. The counts do not by themselves establish causation, comparative safety, or whether an event was more or less frequent than under another strategy.

The figures also do not provide a complete account of precision. Confidence intervals and statistical analyses are not reported in the registry record. The denominator basis for the percentages attached to serious-event terms is not stated. The record does not clarify whether people could contribute to both serious and other categories, and it does not provide a separate all-adverse-event result that can be unambiguously matched to the primary outcome wording.

Timing needs caution: the registry gives a primary outcome timeframe of 28 weeks, while the official title and intervention description state 4 months. The registry record does not explain the difference. This affects how readers should understand the observation window and prevents a confident assumption that all outcome reporting covers the same period.

The study’s stated aim was to explore safety and tolerability and generate data in a population described as resembling routine medical care. The registry record does not provide details sufficient to evaluate that resemblance. Its results are therefore best read as descriptive evidence from the recorded study population, not as proof of a general treatment effect or a complete characterization of safety in every clinical setting.

13. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the difference between describing events and estimating comparative effects. A single-group safety study can record which events occurred among treated participants and how many participants were affected. That information can contribute to safety characterization, but it cannot answer the same question as a randomized comparison. The design determines which conclusions the data can support.

The distinction is especially important for adverse events, which may occur because of treatment, the underlying condition, other health circumstances, or background risk. A comparator can help distinguish a treatment-associated difference from events that would also occur without that treatment strategy. Here, the registry identifies a non-randomized, single-group design and flags the absence of a like-for-like control comparison. The event counts should therefore remain descriptive.

The record also demonstrates why endpoint definitions and timing matter. The primary outcome concerns participants with adverse events, with a specific description of serious events, while the posted adverse-event figures separate serious and other events. The primary timeframe is recorded as 28 weeks, but the title and intervention description state 4 months. Without an explanation, readers cannot assume that these descriptions refer to an identical observation period.

Finally, safety results need context about denominators, overlapping categories, missing observations, and statistical uncertainty. The record gives participants at risk and affected counts, but does not report confidence intervals, missing-data methods, or a multiplicity plan. Term-specific percentages are listed without their denominator basis. Recognizing these limits helps prevent descriptive counts from being mistaken for precise causal estimates. The useful statistical conclusion is bounded: the registry records these adverse-event observations in the studied group, while comparative interpretation remains unavailable.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is the single-group, non-randomized design. Without a control group, the adverse-event counts cannot estimate a comparative effect or distinguish treatment-associated events from background events. The study is open-label, so awareness of treatment may influence symptom reporting or assessment; the registry record does not report whether this affected the results.

There is an unresolved timing difference. The official title and intervention description state 4 months, while the primary outcome timeframe is 28 weeks. The registry record does not explain how these periods relate. The record also does not report a separate observation window for each adverse-event category.

The primary outcome is worded as the number of participants with adverse events, but the available adverse-event data provide separate counts for serious and other events. The registry record does not give a distinct all-adverse-event count that can be unambiguously matched to the primary wording. It does not state whether serious and other categories can overlap, and the serious-term percentages have no reported denominator basis.

Further limitations include the absence of reported confidence intervals, analysis methods, multiplicity procedures, and missing-data methods. The registry record does not describe follow-up completeness or how incomplete observation was handled. It also does not provide a death count in the recorded details. These gaps limit assessment of precision, completeness, and the potential influence of missing observations. They do not prove that relevant analyses or procedures were not conducted outside the registry.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis — NCT01497262.
• Registry record last updated 2015-03-19; status last verified 2015-03.
• Results first posted 2015-03-19.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01497262 is recorded as a completed phase 3, open-label, multi-center, non-randomized, single-group study sponsored by Novartis Pharmaceuticals. It enrolled 162 patients with multiple sclerosis and evaluated fingolimod 0.5 mg taken orally once daily for 4 months. The official title describes a study of safety and tolerability in patients with RRMS. The recorded start is 2012-02, and primary completion is 2014-04.

The primary outcome is the number of participants with adverse events as a measure of safety and tolerability. The registry defines the safety set as all patients who received at least one dose and lists a primary outcome timeframe of 28 weeks. The adverse-event record lists 12 participants with serious events and 63 with other events, with 162 at risk for each category. Serious-event terms and percentages are also listed. The registry does not report a randomized comparison, confidence intervals, missing-data procedures, or an explanation for the difference between the 4-month description and the 28-week timeframe.